No New Tuberculosis Vaccine Approval by FDA, EMA, or PMDA Before 2028: 85% Probability
The global health community has long awaited a breakthrough in tuberculosis (TB) vaccine development. Despite multiple promising candidates currently in late-stage clinical trials, an analysis of regulatory timelines and clinical data suggests that approval of a new TB vaccine by major agencies such as the FDA (United States), EMA (Europe), or PMDA (Japan) before the end of 2027 is highly unlikely, with an estimated 85% probability against such an outcome.
The leading vaccine candidates, including M72/AS01E and VPM1002, are advancing clinical trials but face substantial timing challenges. The M72/AS01E vaccine, which showed approximately 54% protection against active TB in early studies, is in a global Phase 3 trial expected to complete its primary endpoint only by April 2028. This completion date effectively rules out the possibility of FDA, EMA, or PMDA approval before 2028 due to regulatory review durations.
VPM1002, a recombinant BCG vaccine targeting newborns and showing roughly 50.4% efficacy against extrapulmonary TB, has a more favorable timeline. Its Phase 3 PreVenTB trial was anticipated to complete in 2025, raising the possibility of regulatory submission in 2026 followed by review cycles lasting approximately 12 months. However, this scenario requires an exceptionally rapid transition from trial completion to application submission, flawless data, and an uninterrupted regulatory review process. Any delay would push approval beyond 2027.
Other candidates like MTBVAC are also progressing but have no public data indicating readiness for submission before the end of 2026, facing similar regulatory hurdles. Even with regulatory programs designed to expedite review such as FDA's Breakthrough Therapy designation or EMA's PRIME, compressed timelines generally shorten the review by months rather than years, maintaining the overall timeframe constraints.
Regulatory agencies demand completed Phase III trials and extensive safety and efficacy data before granting licensure. Preparation of a Biologics License Application (BLA) or Marketing Authorization Application (MAA) necessitates months of data analysis and dossier compilation prior to submission. Once submitted, the minimum review periods—approximately 12 months for EMA and PMDA, with stringent review for FDA—mean that candidate vaccines completing trials in or after 2026 realistically cannot receive approval before the start of 2028.
It is important to distinguish between Expanded Access Programs (EAP) and full licensure. For example, the FDA's expanded access authorization of a recombinant BCG vaccine (TUBERVAC-rBCG) in early 2025 provides access under limited conditions but does not equate to an approved, marketable vaccine. Such authorizations do not meet the criteria for regulatory approval timelines and thus are excluded from forecasts of licensure.
The biological complexity of TB vaccine development further complicates progress. TB manifests in diverse forms and affects different age groups variably, necessitating large-scale, multi-year studies to confirm broad efficacy and safety. This complexity contributes to the slow pace toward approval despite significant investments and prioritization by the World Health Organization and other entities.
In weighing all factors, the probability of no new TB vaccine obtaining regulatory approval by FDA, EMA, or PMDA before 2028 stands at a high 85%. Achieving approval within this period would require an unprecedentedly swift and flawless sequence of trial completion, data analysis, submission, and regulatory review, which current timelines and operational realities do not support. The most advanced candidates' schedules and typical regulatory review durations form a consistent barrier to earlier approval.
